Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 On...
Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated...
Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply...
WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney...
Barchart Research What to Expect from PROK Earnings PROK Generated May 15, 2026 Current Price $1.6600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Loss Narrative Continues,...
Barchart Research What to Expect from PROK Earnings PROK Generated May 15, 2026 Current Price $1.6600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Loss Narrative Continues,...
Barchart Research What to Expect from PROK Earnings PROK Generated May 15, 2026 Current Price $1.6600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Loss Narrative Continues,...
On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 Peer-reviewed results from the Phase...
On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2...
Barchart Research What to Expect from PROK Earnings PROK Generated May 8, 2026 Current Price $1.8600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Earnings Call Will...